Stem cell technology for the treatment of acute and chronic renal failure.
Stem cell technology for the treatment of acute and chronic renal failure.
复制标题
DOI：
10.1016/j.trsl.2010.07.005
复制
发表时间：
2010-09
期刊：
影响因子：
--
通讯作者：
Humes HD
中科院分区：
文献类型：
--
作者：
Pino CJ;Humes HD
急性和慢性肾衰竭是发病率和死亡率高的疾病。目前的治疗是基于常规透析，以提供容量调节和小溶质清除。越来越多的人认识到，肾衰竭是一种复杂的疾病状态，需要多因素治疗来解决传统单因素方法的缺点。肾移植仍然是最有效的治疗方法，但器官供应远远落后于需求。许多关键的肾脏功能，包括再生、产氨、谷胱甘肽代谢、重要肽类激素的代谢、生长因子和对多器官稳态和免疫调节至关重要的细胞因子由肾小管细胞提供。因此，基于细胞的治疗是有前途的多因素治疗方法。在这篇综述中，目前的干细胞技术，包括成人干细胞，胚胎干细胞和诱导多能干细胞将被讨论作为治疗急性和慢性肾功能衰竭的细胞来源。
Acute and chronic renal failure are disorders with high rates of morbidity and mortality. Current treatment is based upon conventional dialysis to provide volume regulation and small solute clearance. There is growing recognition that renal failure is a complex disease state requiring a multifactorial therapy to address the short-comings of the conventional monofactorial approach. Kidney transplantation remains the most effective treatment, however, organ availability lags far behind demand. Many key kidney functions including gluconeogenesis, ammoniagenesis, metabolism of glutathione, catabolism of important peptide hormones, growth factors, and cytokines critical to multiorgan homeostasis and immunomodulation are provided by renal tubule cells. Therefore, cell-based therapies are promising multifactorial treatment approaches. In this review, current stem cell technologies including adult stem cells, embryonic stem cells and induced pluripotent stem cells will be discussed as cell sources for the treatment of acute and chronic renal failure.
登录
查看更多内容
影响因子：
3.4
作者：
Amiel, GE;Yoo, JJ;Atala, A
通讯作者：
Atala, A
影响因子：
19.6
作者：
Hammerman, MR
通讯作者：
Hammerman, MR
影响因子：
2.6
作者：
Fahy, Gregory M.;Wowk, Brian;Wu, Jun
通讯作者：
Wu, Jun
影响因子：
8.8
作者：
Gerecht-Nir, S;Itskovitz-Eldor, J
通讯作者：
Itskovitz-Eldor, J
DOI：
10.1073/pnas.84.22.7972
发表时间：
1987-11-01
影响因子：
11.1
作者：
GOLDBERG, MA;GLASS, GA;BUNN, HF
通讯作者：
BUNN, HF